Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CLNN | Common Stock | Purchase | $1.2M | +1.5M | +28.34% | $0.80 | 6.79M | Jun 16, 2023 | Direct | |
holding | CLNN | Common Stock | 150K | Jun 16, 2023 | By Trust | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CLNN | Warrants (Right to buy) | Award | +1.5M | 1.5M | Jun 16, 2023 | Common Stock | 1.5M | $1.50 | Direct | F2, F3 | |||
transaction | CLNN | Warrants (Right to buy) | Award | +1.5M | 1.5M | Jun 16, 2023 | Common Stock | 1.5M | $1.10 | Direct | F2, F4 |
Id | Content |
---|---|
F1 | The securities are owned by the Matlin Family Trust 2020. Mr. Matlin in the trustee of the Matlin Family Trust 2020. The shares owned by the Matlin Family Trust 2020 may be deemed to be beneficially owned by Mr. Matlin. |
F2 | The price for each Unit is $0.80; one Unit consists of one share of Common Stock of Clene, one Tranche A Warrant and one Tranche B Warrant. |
F3 | The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche B Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.50 per share. The Tranche B Warrant will expire on the earlier of (a) June 16, 2030, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. |
F4 | The reporting person purchased a unit consisting of one share of Common Stock of Clene Inc., one Tranche A Warrant, and one Tranche B Warrant. The Tranche A Warrant is for 1,500,000 shares of Common Stock of Clene Inc. at an exercise price of $1.10 per share. The Tranche A Warrant will expire on the earlier of (a) June 16, 2026, or (b) 60 days after the Food and Drug Administration accepts a New Drug Application from Clene Inc. |